RII Retinamide retinoid: SPTA received FDA clearance to test RII Retinamide

MDSs are a group of fatal conditions characterized by the inability to produce normal blood cells, which leads to bone marrow failure or leukemia.

SPTA said it needs additional financing before starting the trial, which it wants to begin in the first half of 1996. ...